Dexpramipexole

产品说明书

Print
Chemical Structure| 104632-28-2 同义名 : (R)-普拉克索 ;(R)-Pramipexole; R-(+)-Pramipexole; KNS-760704
CAS号 : 104632-28-2
货号 : A689993
分子式 : C10H17N3S
纯度 : 98%
分子量 : 211.33
MDL号 : MFCD09033169
存储条件：

Pure form Keep in dark place, sealed in dry, store in freezer, under -20°C

In solvent -20°C:3-6个月-80°C:12个月
溶解度 : -
动物实验配方：
生物活性
描述 Dexpramipexole is a neuroprotective agent and weak non-ergoline dopamine agonist.
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01711866 Advanced Idiopathic Parkinson'... 展开 >>s Disease 收起 << Phase 4 Completed - United States, Alabama ... 展开 >> 505 Anniston, Alabama, United States United States, Florida 506 Atlantis, Florida, United States 508 Miami Springs, Florida, United States United States, Georgia 502 Atlanta, Georgia, United States United States, Ohio 501 Dayton, Ohio, United States United States, Oklahoma 509 Oklahoma City, Oklahoma, United States Korea, Republic of 101 Busan, Korea, Republic of 102 Busan, Korea, Republic of 108 Daegu, Korea, Republic of 109 Daegu, Korea, Republic of 105 Gyeonggi-Do, Korea, Republic of 103 Seoul, Korea, Republic of 104 Seoul, Korea, Republic of 106 Seoul, Korea, Republic of 107 Seoul, Korea, Republic of Malaysia 202 Sarawak, Malaysia Singapore 401 Singapore, Singapore 403 Singapore, Singapore Taiwan 301 Linkou, Taiwan 304 Taichung, Taiwan 305 Taipei, Taiwan 收起 <<
NCT01711866 - Completed - -
NCT00144209 Restless Legs Syndrome Phase 3 Completed - Switzerland ... 展开 >> Boehringer Ingelheim Investigational Site Basel, Switzerland, 4025 Boehringer Ingelheim Investigational Site Basel, Switzerland, 4031 Boehringer Ingelheim Investigational Site Bern, Switzerland, 3000 Boehringer Ingelheim Investigational Site Lugano, Switzerland, CH-6900 Boehringer Ingelheim Investigational Site Zurich, Switzerland, 8091 Boehringer Ingelheim Investigational Site Zurzach, Switzerland, 5330 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

4.73mL

0.95mL

0.47mL

23.66mL

4.73mL

2.37mL

47.32mL

9.46mL

4.73mL
参考文献

[1]Alavian KN, Dworetzky SI, et al. Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency. Brain Res. 2012 Mar 29;1446:1-11.

[2]Cudkowicz M, Bozik ME, et al. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med. 2011 Nov 20;17(12):1652-6.